Thymosin Beta-4: The Body’s Own Repair Factor
A naturally occurring peptide that supports muscle, tendon, and broader tissue regeneration with an impressive safety profile.
Thymosin Beta‑4 (TB4) is a 43‑amino‑acid peptide that the thymus produces naturally, and it can also be supplied synthetically as TB500. Dr. Jason Schuster explains why this molecule has become a go‑to tool for athletes and clinicians seeking faster, safer healing of musculoskeletal and systemic injuries.
Natural Origin & Synthetic Variant
TB4 is a peptide found in the human (and bovine) thymus gland; its levels are highest in youth when the organ is larger. The synthetic analogue TB500 shortens the amino‑acid chain to increase stability and duration of action, but Dr. Schuster notes that natural TB4 is generally preferred when possible.
- TB4 – native peptide from thymus
- TB500 – synthetic, longer‑lasting version
- Both share the same core biological activity
How It Works
According to Dr. Schuster, TB4 up‑regulates actin, which helps cells migrate to sites of injury. It promotes angiogenesis, improves cardiomyocyte function, reduces scar formation, and exerts cytoprotective and anti‑inflammatory effects across many tissue types.
- Actin up‑regulation → enhanced cell migration
- Angiogenesis → better blood supply to damaged tissue
- Cytoprotection & anti‑inflammatory signaling
- Supports collagen matrix formation
Therapeutic Applications
Dr. Schuster lists a wide range of conditions in which TB4 has shown benefit in animal studies and clinical use, highlighting its safety and effectiveness compared with many conventional drugs.
- Tendon, ligament and muscle repair for athletes
- Spinal cord and brain injury recovery (stroke, concussion)
- Cardioprotective effects and improved heart function
- Neurodegenerative support (MS, Parkinson’s, Alzheimer’s)
- Immune modulation, sepsis, chemical burns, diabetes, transplant healing
- Liver (NAFLD), lung inflammation, and eye disorders
- Hair regrowth (via related peptide GHK)
Typical Regimens & Safety
The literature cited by Dr. Schuster reports daily sub‑cutaneous doses ranging from 40 µg up to 1,400 µg, often delivered in 14‑day cycles. Specific clinician recommendations include 300 µg once daily, 700 µg daily for 20‑30 days followed by a month off, or 750 µg daily. Across these ranges, no serious adverse events have been documented.
- 40 µg – 1,400 µg per day (most common clinical window)
- 300 µg daily sub‑Q (one cited study)
- 700 µg daily for 20‑30 days, then 30‑day break (Dr. Edwin Lee)
- 750 µg daily (another practitioner recommendation)
- Cycle durations typically 8‑14 days on, equal period off; avoid >3 months continuous use
Safety & Regulatory Notes
Dr. Schuster emphasizes that TB4 has shown no lethal or serious adverse effects in animal studies, with the lethal dose far exceeding therapeutic levels. It appears safe in pediatrics, though data are limited. He advises cycling and notes that FDA warnings are viewed by him as driven by patent and profit concerns rather than safety evidence.
- No serious side effects reported; mild belly ache possible
- Not studied extensively in children; use with caution
- Cycle use (e.g., 8 weeks on, 8 weeks off) to avoid long‑term suppression
- FDA labeling is considered overly restrictive by the presenter
“TB4 up‑regulates actin, drives cells directly to the injury site, and does so with virtually no reported toxicity.”— Dr. Jason Schuster
Go deeper than the summary
Dr. Schuster's board-certified, accredited peptide therapy courses — the full research, dosing, and video breakdowns.